LifeStance Health Group (NASDAQ:LFST) Director Sells 12,371 Shares

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 12,371 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $7.00, for a total value of $86,597.00. Following the completion of the transaction, the director directly owned 1,375,989 shares of the company’s stock, valued at approximately $9,631,923. This trade represents a 0.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Robert Bessler also recently made the following trade(s):

• On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.01, for a total value of $558,206.30.

LifeStance Health Group Stock Performance

LFST stock traded down $0.04 during midday trading on Tuesday, hitting $6.88. The stock had a trading volume of 2,536,438 shares, compared to its average volume of 1,978,562. LifeStance Health Group, Inc. has a 52 week low of $3.74 and a 52 week high of $8.30. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 0.18. The stock has a 50-day simple moving average of $5.90 and a 200 day simple moving average of $5.34. The firm has a market capitalization of $2.68 billion, a price-to-earnings ratio of -229.33 and a beta of 1.13.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. The company had revenue of $363.81 million during the quarter, compared to the consensus estimate of $355.06 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The firm’s revenue for the quarter was up 16.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.02) EPS. As a group, equities research analysts anticipate that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Wall Street Zen downgraded LifeStance Health Group from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. BTIG Research boosted their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeStance Health Group in a research report on Monday. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. Finally, UBS Group upped their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.83.

Hedge Funds Weigh In On LifeStance Health Group

Several institutional investors and hedge funds have recently modified their holdings of LFST. AustralianSuper Pty Ltd acquired a new position in LifeStance Health Group during the third quarter valued at approximately $17,056,000. Vanguard Group Inc. raised its holdings in shares of LifeStance Health Group by 19.5% during the 3rd quarter. Vanguard Group Inc. now owns 14,613,535 shares of the company’s stock worth $80,374,000 after buying an additional 2,383,728 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of LifeStance Health Group by 62.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock worth $26,363,000 after buying an additional 1,839,465 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in LifeStance Health Group by 27.2% in the third quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after buying an additional 1,790,694 shares in the last quarter. Finally, Integral Health Asset Management LLC bought a new position in shares of LifeStance Health Group in the third quarter worth about $8,250,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.